MannKind Corp (MNKD)

• Market cap: $1.25B
• 1 day: -1.22%
• 5 days: -6.7%
• 1 month: 1%
• 3 months: 53.03%
• 6 months: -28.37%
• Year to date: -27.86%
• 1 year: 0.25%
• 5 years: -11.6%
• 10 years: -24.49%
• Sector: Healthcare
• Industry: Biotechnology

About: MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Employees: 592